Search results with tag "Highlights of prescribing information"
1 HIGHLIGHTS OF PRESCRIBING INFORMATION ...
pi.lilly.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FORTEO safely and effectively. See full prescribing information ... Warnings and Precautions, Osteosarcoma (5.1) 11/2020 Warnings and Precautions, Hypercalcemiaand Cutaneous Calcification(5.2)
HIGHLIGHTS OF PRESCRIBING INFORMATION heart failure …
www.novo-pi.com17 PATIENT COUNSELING INFORMATION *Sections or subsections omitted from the full prescribing information are not listed. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NOVOLOG ® safely and effectively. See full prescribing information for NOVOLOG ®.
HIGHLIGHTS OF PRESCRIBING INFORMATION The …
www.regeneron.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PRALUENT safely and effectively. See full prescribing information for PRALUENT. ... The mean age of the population was 59 years, 40% of the population were women, 90% were White, 4% were Black or African American, and
HIGHLIGHTS OF PRESCRIBING INFORMATION - LENVIMA
www.lenvima.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LENVIMA safely and effectively. See full prescribing information for ... Warnings and Precautions (5.14) 2/2020 Warnings and Precautions (5.15) 12/2020 ...
HIGHLIGHTS OF PRESCRIBING INFORMATION TIVDAK ...
seagendocs.comHIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use TIVDAK safely and effectively. See full prescribing information for TIVDAK. TIVDAK ® (tisotumab vedotin -tftv) for injection, for intravenous use Initial U.S. Approval: 2021 • WARNING: OCULAR TOXICITY
HIGHLIGHTS OF PRESCRIBING INFORMATION …
radiuspharm.comHIGHLIGHTS OF PRESCRIBING INFORMATION. These highlights do not include all the information needed to use TYMLOS safely and effectively. See full prescribing information for TYMLOS. TYMLOS ... Warnings and Precautions, Osteosarcoma (5.1) 12/2021
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
docs.boehringer-ingelheim.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JARDIANCE safely and effectively. See full prescribing information for JARDIANCE. JARDIANCE® (empagliflozin tablets), for oral use Initial U.S. Approval: 2014 ---- …
HIGHLIGHTS OF PRESCRIBING INFORMATION AUSTEDO.
www.accessdata.fda.gov1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AUSTEDO safely and effectively. See full prescribing information for
HIGHLIGHTS OF PRESCRIBING INFORMATION - Qsymia
qsymia.comHIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use QSYMIA ® safely and effectively. See full prescribing information for QSYMIA. QSYMIA (phentermine and topiramate extended-release) capsules, for oral use, CIV . Initial U.S. Approval: 2012 .
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.crofab.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CROFAB safely and effectively. See full …
HIGHLIGHTS OF PRESCRIBING INFORMATION
www.fda.govCangene Corporation Confidential and Proprietary Page 1 of 18 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use
HIGHLIGHTS OF PRESCRIBING INFORMATION
www.accessdata.fda.govTo report SUSPECTED ADVERSE REACTIONS, contact Gilead . HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.merck.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MAXALT and MAXALT-MLT safely and effectively.
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
www.kineretrx.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ... 5 WARNINGS AND PRECAUTIONS 5.1 Serious Infections 5.2 Use with TNF Blocking Agents 5.3 Hypersensitivity Reactions 5.4 Immunosuppression 5.5 Immunizations .
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.merck.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EMENDCAPSULES and EMEND …
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.azpicentral.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MERREM I.V. safely and effectively. See full …
HIGHLIGHTS OF PRESCRIBING INFORMATION ... - LUNESTA
www.lunesta.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LUNESTA occur (5.safely and effectively.
HIGHLIGHTS OF PRESCRIBING INFORMATION - …
www.fda.govHIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use HPC, Cord Blood safely and effectively.
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
www.ilumya.comFULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Dosage 2.2 Tuberculosis Assessment Prior to Initiation of ILUMYA 2.3 Important Administration Instructions 2.4 Preparation and Administration of ILUMYA 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND …
HIGHLIGHTS OF PRESCRIBING INFORMATION - Acetadote
www.acetadote.comACETADOTE® (acetylcysteine) Injection Package Insert, page 3 of 12 If the timing of the acute acetaminophen ingestion is known and the results of the acetaminophen assay are available within 8 hours: Refer to the Rumack-Matthew nomogram (see Figure …
HIGHLIGHTS OF PRESCRIBING INFORMATION
www.amneal.comEstrogen Plus Progestin Therapy • Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia (5.2, 5.4) • The WHI estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism (PE) and myocardial infarction (MI) (5.2) • The WHI estrogen plus progestin substudy reported increased risks of invasive breast ...
HIGHLIGHTS OF PRESCRIBING INFORMATION …
regranex.comof gel should be used for 15g tubes (1 × 2 × 0.6 = 1 1/4) and 2 3/4 inch gel length should be used for a 2g tube (1 × 2 × 1.3 = 2 3/4). Table 2: Formula to Calculate Length of Gel in Centimeters to Be Applied Daily
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.accessdata.fda.govFULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE . TIVICAY ® is indicated in combination with other antiretroviral agents for the treatment
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.accessdata.fda.govFULL PRESCRIBING INFORMATION Tyvaso™ (treprostinil) inhalation solution For Oral Inhalation Only 1 INDICATIONS AND USAGE . Tyvaso is indicated to increase walk distance in patients with WHO Group I pulmonary arterial
HIGHLIGHTS OF PRESCRIBING INFORMATION • for …
pi.apellis.comIf hemolysis, including elevated LDH, occurs after discontinuation of EMPAVELI, consider restarting treatment with EMPAVELI. 5.5 Interference with Laboratory Tests There may be interference between silica reagents in coagulation panels and EMPAVELI that results in
HIGHLIGHTS OF PRESCRIBING INFORMATION
eligardhcp.combe rubbed or compressed (i.e., with a belt or clothing waistband). 2.1 Mixing Procedure . Use aseptic technique throughout the procedure. As with other similar agents, the use of gloves is recommended during mixing and administration. 1 Allow the product to reach room temperature before mixing. Once mixed, the product must be administered within
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.fda.govimmediately), so place the cap on its top on a clean surfacein a spot where it would be least likely to become environmentally contaminated. 8.